Prestige Consumer Healthcare Inc.
PBH · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 7.62 | -0.05 | 0.27 | 0.52 |
| FCF Yield | 5.69% | 6.71% | 7.10% | 9.41% |
| EV / EBITDA | 14.42 | 12.46 | 312.49 | 11.77 |
| Quality | ||||
| ROIC | 7.70% | 8.10% | 9.42% | 7.28% |
| Gross Margin | 55.76% | 55.49% | 55.45% | 57.11% |
| Cash Conversion Ratio | 1.17 | 1.19 | -2.79 | 1.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.30% | 1.17% | 6.13% | 4.11% |
| Free Cash Flow Growth | 1.64% | 7.86% | -11.33% | 17.30% |
| Safety | ||||
| Net Debt / EBITDA | 2.61 | 2.92 | 92.25 | 4.21 |
| Interest Coverage | 7.07 | 5.10 | 4.99 | 5.13 |
| Efficiency | ||||
| Inventory Turnover | 3.41 | 3.61 | 3.10 | 3.87 |
| Cash Conversion Cycle | 155.73 | 130.01 | 126.25 | 97.36 |